Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas

Primary central nervous system lymphoma (PCNSL) manifest aggressive clinical behaviour and have poor prognosis. Although constitutive activation of the nuclear factor‐κB (NF‐κB) pathway has been documented, knowledge about the genetic alterations leading to the impairment of the NF‐κB pathway in PCNSLs is still limited. This study was aimed to unravel the underlying genetic profiles of PCNSL.

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  K. Ichimura,et al.  Revisiting TP53 Mutations and Immunohistochemistry—A Comparative Study in 157 Diffuse Gliomas , 2015, Brain pathology.

[3]  B. Quesnel,et al.  MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome , 2014, British journal of haematology.

[4]  R. Eils,et al.  The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing , 2014, Leukemia.

[5]  K. Hoang-Xuan,et al.  Mutational analysis of primary central nervous system lymphoma , 2014, Oncotarget.

[6]  T. Terada,et al.  Recent Trends in Neuroendovascular Therapy in Japan: Analysis of a Nationwide Survey—Japanese Registry of Neuroendovascular Therapy (JR-NET) 1 and 2 , 2013, Neurologia medico-chirurgica.

[7]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[8]  M. Kersten,et al.  High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites , 2013, Blood Cancer Journal.

[9]  Steven J. M. Jones,et al.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. , 2013, Blood.

[10]  David Dunson,et al.  Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[11]  D. Begley,et al.  Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  R. Siebert,et al.  Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma , 2012, Acta Neuropathologica.

[13]  K. Hoang-Xuan,et al.  Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas , 2012, Clinical Cancer Research.

[14]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[15]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[16]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[17]  R. Siebert,et al.  Mutations of CARD11 but not TNFAIP3 may activate the NF-κB pathway in primary CNS lymphoma , 2010, Acta Neuropathologica.

[18]  Jan Delabie,et al.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.

[19]  F. Cavalli,et al.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial , 2009, The Lancet.

[20]  S. Ogawa,et al.  Frequent inactivation of A20 in B-cell lymphomas , 2009, Nature.

[21]  B. Coiffier,et al.  Recent developments in the treatment of aggressive non-Hodgkin lymphoma. , 2009, Blood reviews.

[22]  W. Klapper,et al.  Recurrent Inactivation of the PRDM1 Gene in Primary Central Nervous System Lymphoma , 2008, Journal of neuropathology and experimental neurology.

[23]  Jan Delabie,et al.  Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.

[24]  C. Meijer,et al.  Tailoring of (immune-)therapy in R-CHOP refractory diffuse large B-cell lymphoma (DLBCL) patients , 2008 .

[25]  L. Pham,et al.  Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma. , 2007, Blood.

[26]  D. Nelson,et al.  Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  David G. Schatz,et al.  Targeting of somatic hypermutation , 2006, Nature Reviews Immunology.

[28]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[29]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.